PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium. Electronic address: kvandyck@aligos.com.\', \'Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.\', \'Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.\', \'CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium.\', \'Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA.\', \'Centre for Drug Design and Discovery (CD3), KU Leuven, Gaston Geenslaan 2, 3001 Leuven, Belgium; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium.\', \'Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium.\', \'Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: johan.neyts@kuleuven.be.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0006-291X(21)00492-710.1016/j.bbrc.2021.03.096
?:hasPublicationType
?:journal
  • Biochemical and biophysical research communications
is ?:pmid of
?:pmid
?:pmid
  • 33813272
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.087
?:rankingScore_hIndex
  • 237
is ?:relation_isRelatedTo_publication of
?:title
  • ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33813272>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33813272>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all